|
|
Registro Completo |
Biblioteca(s): |
Ebooks. |
Data corrente: |
01/02/2013 |
Data da última atualização: |
01/02/2013 |
Autoria: |
LUSTGARTEN, J.; CUI, Y.; LI, S. |
Afiliação: |
Joseph Lustgarten; Yan Cui; Shulin Li. |
Título: |
Targeted Cancer Immune Therapy. |
Ano de publicação: |
2009 |
Fonte/Imprenta: |
Springer eBooks. |
Páginas: |
XI, 343 p. |
Descrição Física: |
digital. |
ISBN: |
9781441901705 |
DOI: |
10.1007/978-1-4419-0170-5 |
Idioma: |
Inglês |
Conteúdo: |
Cancer has surpassed heart disease as the number one killer in the world, and standard cancer therapy such as radiation, chemotherapy, and surgery may have reached its plateau in further improving the outcome of treated patients. Biological therapies combined with other treatment approaches may be the next X-factor to greatly extend survival time and improve patients’ quality of life. One of the most developed fields in biological therapy is immune therapy, which has stemmed into many branches due to its significance and the tremendous effort by a large population of scientists. Tumor-targeted antibody therapy has been successfully used for treating some types of tumors, and the first tumor vaccine against ovarian cancer has been developed for clinical application. Targeted Cancer Immune Therapy provides comprehensive coverage of novel immune therapeutic approaches, including cytokine therapy, engineered cell therapy, and the application of tumor-targeted antibodies for generating tumor-specific cell therapy, TLR ligand therapy, and cytokine therapy. In the section "Cytokine Immune Therapy," the authors review relatively new cytokine family members, such as the IL12 family, IL18, IL21, IL24, IL28, and IL29, in regard to the anti-tumor function and application in treating tumors. The strategy for targeting and retaining cytokines in the tumor microenvironment is also reviewed. The section "Cell-based Immune Therapy" focuses on reviewing "state of the art" approaches for engineering potent immune regulatory or effector cells, such as dendritic cells, T cells, and stem cells, for tumor targeting and initiation of tumor specific immune response. In the section "Targeted Immune Therapy," the authors rearticulate antibody therapy for boosting immune response, which includes immunocytokines, "T-body," and tumor targeted CpG ODN. Some or all of these innovative approaches may ultimately become effective future immune therapies for treating malignancy. MenosCancer has surpassed heart disease as the number one killer in the world, and standard cancer therapy such as radiation, chemotherapy, and surgery may have reached its plateau in further improving the outcome of treated patients. Biological therapies combined with other treatment approaches may be the next X-factor to greatly extend survival time and improve patients’ quality of life. One of the most developed fields in biological therapy is immune therapy, which has stemmed into many branches due to its significance and the tremendous effort by a large population of scientists. Tumor-targeted antibody therapy has been successfully used for treating some types of tumors, and the first tumor vaccine against ovarian cancer has been developed for clinical application. Targeted Cancer Immune Therapy provides comprehensive coverage of novel immune therapeutic approaches, including cytokine therapy, engineered cell therapy, and the application of tumor-targeted antibodies for generating tumor-specific cell therapy, TLR ligand therapy, and cytokine therapy. In the section "Cytokine Immune Therapy," the authors review relatively new cytokine family members, such as the IL12 family, IL18, IL21, IL24, IL28, and IL29, in regard to the anti-tumor function and application in treating tumors. The strategy for targeting and retaining cytokines in the tumor microenvironment is also reviewed. The section "Cell-based Immune Therapy" focuses on reviewing "state of the art" approaches... Mostrar Tudo |
Palavras-Chave: |
Biomedicine; Cancer Research; Oncology; Pharmacology/Toxicology. |
Thesaurus Nal: |
medicine; toxicology. |
Categoria do assunto: |
-- |
URL: |
https://dx.doi.org/10.1007/978-1-4419-0170-5
|
Marc: |
LEADER 02627nam a2200241 a 4500 001 1947371 005 2013-02-01 008 2009 bl uuuu u0uu1 u #d 020 $a9781441901705 024 7 $a10.1007/978-1-4419-0170-5$2DOI 100 1 $aLUSTGARTEN, J. 245 $aTargeted Cancer Immune Therapy.$h[electronic resource] 260 $aSpringer eBooks.$c2009 300 $aXI, 343 p.$cdigital. 520 $a<P>Cancer has surpassed heart disease as the number one killer in the world, and standard cancer therapy such as radiation, chemotherapy, and surgery may have reached its plateau in further improving the outcome of treated patients. Biological therapies combined with other treatment approaches may be the next X-factor to greatly extend survival time and improve patients’ quality of life. One of the most developed fields in biological therapy is immune therapy, which has stemmed into many branches due to its significance and the tremendous effort by a large population of scientists. Tumor-targeted antibody therapy has been successfully used for treating some types of tumors, and the first tumor vaccine against ovarian cancer has been developed for clinical application.</P> <P>Targeted Cancer Immune Therapy provides comprehensive coverage of novel immune therapeutic approaches, including cytokine therapy, engineered cell therapy, and the application of tumor-targeted antibodies for generating tumor-specific cell therapy, TLR ligand therapy, and cytokine therapy. In the section "Cytokine Immune Therapy," the authors review relatively new cytokine family members, such as the IL12 family, IL18, IL21, IL24, IL28, and IL29, in regard to the anti-tumor function and application in treating tumors. The strategy for targeting and retaining cytokines in the tumor microenvironment is also reviewed. The section "Cell-based Immune Therapy" focuses on reviewing "state of the art" approaches for engineering potent immune regulatory or effector cells, such as dendritic cells, T cells, and stem cells, for tumor targeting and initiation of tumor specific immune response. In the section "Targeted Immune Therapy," the authors rearticulate antibody therapy for boosting immune response, which includes immunocytokines, "T-body," and tumor targeted CpG ODN. Some or all of these innovative approaches may ultimately become effective future immune therapies for treating malignancy.</P> 650 $amedicine 650 $atoxicology 653 $aBiomedicine 653 $aCancer Research 653 $aOncology 653 $aPharmacology/Toxicology 700 1 $aCUI, Y. 700 1 $aLI, S.
Download
Esconder MarcMostrar Marc Completo |
Registro original: |
Ebooks (Ebooks) |
|
Nenhum exemplar cadastrado para este documento. |
Voltar
|
|
Registros recuperados : 1 | |
1. | | LOUZADA, E. F.; VENTURIERI, A.; ROCHA, G. de M. Apontamento das políticas de compras institucionais sustentáveis para comunidades tradicionais, como a agricultura familiar, em prol do desenvolvimento local. In: SEMINÁRIO INTERNACIONAL DE DESENVOLVIMENTO RURAL SUSTENTÁVEL COOPERATIVISMO E ECONOMIA SOLIDÁRIA, 15.; FEIRA DE CIÊNCIA, TECNOLOGIA E INOVAÇÃO SOCIAL, 6., 2022, Castanhal. [Anais...]. Castanhal, 2022. XV SICOOPES.Tipo: Artigo em Anais de Congresso |
Biblioteca(s): Embrapa Amazônia Oriental. |
| |
Registros recuperados : 1 | |
|
Nenhum registro encontrado para a expressão de busca informada. |
|
|